DNA damage detected with γH2AX in endometrioid adenocarcinoma cell lines

International Journal of Oncology

Volumn 36, Issue 5, 2010, Pages 1081-1088

  Ikeda, Maki ^a   Kurose, Akira ^a   Takatori, Eriko ^a   Sugiyama, Toru ^a   Traganos, Frank ^b   Darzynkiewicz, Zbigniew ^b   Sawai, Takashi ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

H2AX; 5 fluorouracil; Cell cycle; Cisplatin; Doxorubicin; Endometrioid adenocarcinoma

Indexed keywords

BETA GALACTOSIDASE; CELL DNA; CISPLATIN; DOXORUBICIN; FLUOROURACIL; HISTONE H2AX; MITOXANTRONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL AGING; CONTROLLED STUDY; DNA DAMAGE; ENDOMETRIOID CARCINOMA; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL;

ADENOCARCINOMA; APOPTOSIS; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; FLUOROURACIL; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; TIME FACTORS;

EID: 77950416893     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000589     Document Type: Article

References (33)

1. Center for cancer control and information services, National Cancer Center, Japan. (http://ganjoho.jp/professional/statistics/odjrh3000000hwsa-att/ cancer-incidence(1975-2004).xls).
2. The Gynecologic Oncology Committee report of Japan Society of Obstetrics and Gynaecology. J Obstet Gynaecol 56: 89, 2004.
3. Ostling O and Johanson KJ: Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 123: 291-298, 1984.
4. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998.
5. Kurose A, Tanaka T, Huang X, Halicka HD, Traganos F, Dai W and Darzynkiewicz Z: Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase and apoptosis. Cytometry A 68: 1-9, 2005.
6. Huang X, Okafuji M, Traganos F, Luther E, Holden E and Darzynkiewicz Z: Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry A 58: 99-110, 2004.
7. Sedelnikova OA, Rogakou EP, Panyutin IG and Bonner WM: Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res 158: 486-492, 2002.
8. Rogakou EP, Boon C, Redon C and Bonner WM: Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146: 905-916, 1999.
9. Banáth JP and Olive PL: Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 63: 4347-4350, 2003.
10. Thigpen JT, Brady MF, Homesley HD, et al: Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22: 3902-3908, 2004.
11. Thigpen JT, Blessing JA, Homesley H, et al: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma (a Gynecologic Oncology Group study). Gynecol Oncol 33: 68-70, 1989.
12. Dimri GP, Lee X, Basile G, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995.
13. Rothkamm K and Löbrich M: Evidence for a lack of DNA double-strand break repair in human cells exposed to very low X-ray doses. Proc Natl Acad Sci USA 100: 5057-5062, 2003.
14. Hideki M: Mechanism of DNA damage and apoptosis induced by anticancer drugs through generation of reactive oxygen species. Yakugaku Zasshi 127: 1837-1842, 2007.
15. Huang X, Kurose A, Tanaka T, Traganos F, Dai W and Darzynkiewicz Z: Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine. Cancer Biol Ther 5: 959-964, 2006.
16. Zhao H, Tanaka T, Halicka HD, Traganos F, Zarebski M, Dobrucki J and Darzynkiewicz Z: Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports the aging-related processes. Cytometry A 71: 905-914, 2007.
17. Suresh A, Guedez L, Moreb J and Zukali J: Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment. Br J Haematol 120: 457-463, 2003.
18. Mallery SR, Clark YM, Ness GM, Minshawi OM, Pei P and Hohl CM: Thiol redox modulation of doxorubicin-mediated cytotoxicity in cultured AIDS-related Kaposi's sarcoma cells. J Cell Biochem 73: 259-277, 2002.
19. Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B and Poupon MF: Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 6: 643-653, 2002.
20. Shacter E, Williams JA, Hinson RM, Senturker S and Lee YJ: Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 96: 307-313, 2000.
21. Senturker S, Tschirret-Guth R, Morrow J, Levine R and Shacter E: Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species. Arch Biochem Biophys 397: 262-272, 2002.
22. X Yang, M Fraser, MR Abedini, T Bai and BK Tsang: Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br J Cancer 98: 803-808, 2008.
23. Asselin E, Mills GB and Tsang BK: XIAP regulates Akt activity and capase-3-dependent cleavage during cisplatin-induced apoptosis in human Ovarian epithelial cancer cells. Cancer Res 61: 1862-1868, 2008.
24. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
25. Schafer KA: The cell cycle (Review). Vet Pathol 35: 461-478, 1998.
26. Gonzales VM, Fuertes MA, Alonso C and Perez JM: Is cisplatin induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663, 2001.
27. Branzei D and Foiani M: The checkpoint response to replication stress. DNA Repair 8: 1038-1046, 2009.
28. WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinoma. Oral Oncol 34: 198-203, 1998.
29. WAF1/CIP1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Rep 6: 539-545, 1999.
30. van Oijen MG, Tilanus MG, Medema RH and Slootweg PJ: Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. J Oral Pathol Med 27: 367-375, 1998.
31. Matsuhashi N, Matsuo A, Kawaguchi Y, Sugiyama Y and Saji S: Relation between p53 expression of human colon cancer cell lines and induction of apoptosis by anticancer drugs. Jpn J Cancer Chemother 30: 1855-1858, 2003.
32. Zhao H, Traganos F and Darzynkiewicz Z: Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. Cytometry A 73: 480-489, 2008.
33. Stiff T, Walker SA, Cerosaletti K, et al: ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J 25: 5775-5778, 2006.